Interim Financial Report for Q1 2009 for the BioPorto Group Summary of Q1 2009 Developments for BioPorto in Q1 2009 were predominantly positive. Revenues rose by 33% compared to the same quarter last year (comparative figures in parentheses). Statements by major diagnostics companies that NGAL is the new renal injury marker support BioPorto's expectations of the implementation of NGAL as a routine immunoassay and improve the prospects of concluding the first licensing agreement. At the same time however, BioPorto was inconvenienced by litigation relating to the company's rights to hold the important NGAL cutoff patent. • BioPorto is the holder of IP rights to NGAL as an immunoassay method for acute renal injury and is negotiating for the release of licensing access to these rights. • BioPorto has launched an APC-PCI ELISA Kit. Initial studies in this area have prompted great expectations for the use of APC-PCI as a biomarker for sepsis patients with a view to qualifying them for special treatment. • Revenues in Q1 2009 rose by 33% to T.DKK 2,948 (T.DKK 2,221). • The financial result for the period was a loss of T.DKK 3,613 (T.DKK 4,896 million). • The European Patent Office (EPO) recommend that the issuance process for BioPorto's NGAL cutoff patent be resumed, after having put the process on hold following the filing of a claim by Cincinnati Children's Hospital. • BioPorto has initiated a marketing campaign in China for the company's IVD NGAL ELISA kit, initially by establishing new distributors in this market. During a visit to distributors in May, the possibilities of collaborating on product registration were also evaluated; this collaboration would be decisive to sales for diagnostics use. The country's key opinion leaders are very interested in the NGAL immunoassay, and the ELISA immunoassay format is widely used by central laboratories at the hospitals. Forecasts for the 2009 fiscal year upheld • Final conclusion of the first licensing agreement for the company's IP rights to the NGAL immunoassay method. The company's expectations of licensing income running in the two-digit millions are upheld. • BioPorto anticipates that product sales will continue to grow in 2009 by around 25-35% and revenues are expected to be DKK 12-13.5 million, before income from licensing sales. • A net loss of around DKK 12 million, before possible licensing income, is still expected. About BioPorto BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company's developments include a test (NGAL) to diagnose and monitor acute kidney damage. BioPorto's strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases. BioPorto was founded in 2000 and has about 25 employees. The Company's shares are listed on NASDAQ OMX Copenhagen (symbol: BIOPOR).